No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SAVA240705C4000
- 8.45
- 0.000.00%
15min DelayClose Jul 2 15:59 ET
8.45High8.45Low
8.45Open8.45Pre Close1 Volume0 Open Interest4.00Strike Price845.00Turnover0.00%IV5.60%PremiumJul 5, 2024Expiry Date7.79Intrinsic Value100Multiplier2DDays to Expiry0.66Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.53Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; Once-Monthly Infusions Reduced Amyloid Plaques By...
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Cassava Sciences (NASDAQ:SAVA) has engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employ
Cassava Forms Committee After US Probe, Researcher Fraud
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Why Cassava Sciences Stock Is Sinking Today
Cassava Sciences Down Another 3% as SEC Provides Update on Simufilam Probe
Comments
$Cassava Sciences(SAVA.US$Why would people choose to stay on simufilan on extended trial if the drug didn’t work on a debilitating disease such as AD? AD gets violently worse over time . There’s never been an issue of safety and patient families and doctors testimony that sava works. 1900 people on this are not going to want to get off the drug and get worse again. The drug works
2
$Cassava Sciences(SAVA.US$ If we are going by ethics and integrity, did the DOJ ever investigate this’ Eisai and Biogen’s Alzheimer’s disease drug lecanemab’? Where was the outrage, DOJ investigation and accusations by Bik, Bredt, Adrian , Jesse and Shorts over death of patients in a drug that should have never been approved? 2 years ago when CUNY, SEC and FDA investigated, they found no evidence of wrongdoing or manipulation by SAVA or Wang. DOJ on a Friday afternoon before options expires wit...
4
$Cassava Sciences(SAVA.US$ Cassava Sciences Issues Statement on Former Science Advisor Jun 28, 2024:"Dr. Wang and his former public university medical school have had no involvement in the Company’s Phase 3 clinical trials of simufilam."
2
3
Read more